Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

Global & Regional Health Technology Assessment

Marco Falcone¹  Massimo Andreoni²  Francesco Saverio Mennini³  Andrea Marcellusi³  Martina Paoletti⁴  Chiara Bini⁴ 

[1] Department of Clinical and Experimental Medicine, Infectious Diseases Unit, University of Pisa, Pisa - Italy;Department of Infectious Diseases, University of Rome Tor Vergata, Rome - Italy;Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome “Tor Vergata”, Rome - Italyand Institute for Leadership and Management in Health – Kingston University London, London - UK;Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome “Tor Vergata”, Rome - Italy;

关键词: Antibiotic Resistance;    Antibiotic;    Cost-effectiveness analysis;    Cost-utility analysis;    Nosocomial infections;   

DOI  :  10.33393/grhta.2022.2287

来源: DOAJ

【 授权许可】

Unknown